

Effective date: 7/15/2020
Review date: 5/2020, 9/2020, 12/2020, 5/2021, 6/2022, 12/2022, 8/2023, 2/2024, 1/2025
Scope: Medicaid

SPECIALTY GUIDELINE MANAGEMENT

ENBREL (etanercept)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

1. Moderately to severely active rheumatoid arthritis (RA)
2. Moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in patients aged 2 years or older
3. Active psoriatic arthritis (PsA)
4. Active ankylosing spondylitis (AS)
5. Moderate to severe chronic plaque psoriasis (PsO) in patients aged 4 years and older
6. Juvenile psoriatic arthritis in patients aged 2 years and older (JPsA)

B. Compendial Uses

1. Axial spondyloarthritis
2. Oligoarticular juvenile idiopathic arthritis
3. Reactive arthritis
4. Hidradenitis suppurativa, severe, refractory
5. Behcet's disease
6. Graft versus host disease

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL

For all indications:

- Submission of the member's chart or medical record is required, documenting medical necessity based on the criteria corresponding to the applicable indication
- Enbrel will not be used concomitantly with an injectable biologic response modifier including TNF-inhibitors (e.g., Humira (adalimumab), Remicade (infliximab), etc.) and IL-inhibitors (e.g., Cosentyx (secukinumab), Ustekinumab (e.g., Stelara, Wezlana, etc), Tremfya (guselkumab), Ilumya (tildrakizumab), Skyrizi (risankizumab), Bimzelx (bimekizumab), Omvoh (mirikizumab), etc.) or other oral non-biologic agent (e.g., Otezla (apremilast), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Velsipity (etrasimod), etc.)

Effective date: 7/15/2020
Review date: 5/2020, 9/2020, 12/2020, 5/2021, 6/2022, 12/2022, 8/2023, 2/2024, 1/2025
Scope: Medicaid

- Member has had a documented negative TB test (which can include a tuberculosis skin test [PPD], an interferon-release assay [IGRA], or a chest x-ray)* within 6 months of initiating therapy for persons who are naïve to biologic DMARDs or targeted synthetic DMARDs associated with an increased risk of TB.

* If the screening testing for TB is positive, there must be further testing to confirm there is no active disease. Do not administer the requested medication to members with active TB infection. If there is latent disease, TB treatment must be started before initiation of the requested medication.

A. **Moderately to severely active rheumatoid arthritis (RA)**

Authorization of 12 months may be granted for treatment of moderately to severely active RA when all of the following criteria are met:

- Enbrel is prescribed by, or in consultation with, a specialist in rheumatology.
- Documentation that the member meets either of the following criteria:
 - Member has been tested for either of the following biomarkers and the test was positive:
 - Rheumatoid factor (RF)
 - Anti-cyclic citrullinated peptide (anti-CCP)
 - Member has been tested for ALL of the following biomarkers:
 - RF
 - Anti-CCP
 - C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)
- Documentation that the member meets all of following:
 - Member has experienced an inadequate response to at least a 3-month trial of methotrexate despite adequate dosing (i.e., titrated to 20 mg/week); OR Member has an intolerance or contraindication to methotrexate (see Appendix A)
 - Member has had inadequate response, intolerance, or contraindication to at least a 3-month trial of adalimumab at maximum tolerated doses

B. **Moderately to severely active articular juvenile idiopathic arthritis**

Authorization of 12 months may be granted for the treatment of moderately to severely active articular juvenile idiopathic arthritis when the following criteria are met:

- Enbrel is prescribed by, or in consultation with, a specialist in rheumatology.
- Documentation that the member meets one of the following:
 - The member has had an inadequate response to methotrexate or another non-biologic DMARD administered at an adequate dose and duration.
 - The member has risk factors (See Appendix C) and the member also meets one of the following:
 - High-risk joints are involved (e.g., cervical spine, wrist, or hip).
 - High disease activity.
 - Are judged to be at high risk for disabling joint disease.
- Documentation that the member has had an inadequate response, intolerance, or contraindication at maximum tolerated doses to a minimum (3) month trial of adalimumab.

C. **Active psoriatic arthritis (PsA)**

Authorization of 12 months may be granted for treatment of active psoriatic arthritis (PsA) in members 2 years of age and older when the following are met:

- Enbrel is prescribed by, or in consultation with, a specialist in dermatology or rheumatology.

Effective date: 7/15/2020
Review date: 5/2020, 9/2020, 12/2020, 5/2021, 6/2022, 12/2022, 8/2023, 2/2024, 1/2025
Scope: Medicaid

- b. Documentation that the member has had an inadequate response, intolerance, or contraindication at maximum tolerated doses to a minimum (3) month trial of adalimumab and to a minimum (6) month trial of ustekinumab.

D. Active ankylosing spondylitis (AS) and axial spondyloarthritis

Authorization of 12 months may be granted for treatment of active ankylosing spondylitis and axial spondyloarthritis when the following criteria is met:

- a. Enbrel is prescribed by, or in consultation with, a specialist in rheumatology.
- b. Documentation that the member meets one of the following:
 - i. Member has experienced an inadequate response to at least two non-steroidal anti-inflammatory drugs (NSAIDs).
 - ii. Member has an intolerance or contraindication to two or more NSAIDs.
- c. Documentation that the member has had an inadequate response, intolerance, or contraindication at maximum tolerated doses to a minimum (3) month trial of adalimumab.

E. Moderate to severe chronic plaque psoriasis

Authorization of 12 months may be granted for the treatment of moderate to severe chronic plaque psoriasis when all of the following are met:

- a. Enbrel is prescribed by, or in consultation with, a specialist in dermatology.
- b. Documentation that the member has at least 10 % of body surface area (BSA) is affected OR crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected.
- c. Documentation that the Member meets either of the following criteria:
 - 1. Member has had an inadequate response or intolerance to either phototherapy (e.g., UVB, PUVA) or a pharmacologic treatment with methotrexate, cyclosporine or acitretin.
 - 2. Member has a clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine and acitretin (see Appendix B).
- d. Documentation that the member experienced an inadequate treatment response or intolerance from Zoryve (roflumilast) cream within the last 12 months; **OR**
- e. Documentation that the member experienced an inadequate response, intolerance, or contraindication at maximum tolerated doses to a minimum (3) month trial of adalimumab and to a minimum (6) month trial of ustekinumab. Contraindications, adverse effects and/or intolerance must be documented;

F. Reactive arthritis

- 1. Enbrel is prescribed by, or in consultation with, a specialist in rheumatology.
- 2. Authorization of 12 months may be granted for members with documentation who have previously received a biologic indicated for reactive arthritis.
- 3. Authorization of 12 months may be granted for treatment of reactive arthritis with documentation when any of the following criteria is met:
 - a. Member has experienced an inadequate response to at least a 3-month trial of methotrexate despite adequate dosing (i.e., titrated to 20 mg/week).
 - b. Member has an intolerance or contraindication to methotrexate (see Appendix A).

Effective date: 7/15/2020
Review date: 5/2020, 9/2020, 12/2020, 5/2021, 6/2022, 12/2022, 8/2023, 2/2024, 1/2025
Scope: Medicaid

G. Hidradenitis suppurativa

1. Authorization of 12 months may be granted for treatment of severe, refractory hidradenitis suppurativa when the following is met:
 - a. Enbrel is prescribed by, or in consultation with, a specialist in dermatology.
 - b. Documentation that the member meets one of the following:
 - i. Member has experienced an inadequate response to oral antibiotics for at least 90 days.
 - ii. Member has an intolerance or contraindication to oral antibiotics.
 - c. Documentation that the member has had an inadequate response, intolerance, or contraindication at maximum tolerated doses to a minimum (3) month trial of adalimumab

H. Graft versus host disease

Authorization of 3 months may be granted for treatment of graft versus host disease when either of the following criteria is met: Documentation that the member has experienced an inadequate response to topical or systemic corticosteroids or immunosuppressive therapy (e.g., cyclosporine or mycophenolate mofetil) **OR** Documentation that the member has an intolerance or contraindication to topical or systemic corticosteroids and immunosuppressive therapy (e.g. cyclosporine, mycophenolate mofetil).

I. Behcet's disease

1. Authorization of 12 months may be granted for members who have previously received Otezla or a biologic indicated for the treatment of Behcet's disease.
2. Authorization of 12 months may be granted for the treatment of Behcet's disease when the member has documentation of an inadequate response to at least one nonbiologic medication for Behcet's disease (e.g., apremilast, colchicine, systemic glucocorticoids, azathioprine).

III. DOSING

The prescribed dose and quantity fall within the FDA-approved labeling or within compendia supported dosing guidelines.

IV. CONTINUATION OF THERAPY

A. Moderately to severely active rheumatoid arthritis (RA)

Authorization of 12 months may be granted for all members (including new members) with documentation of using the requested medication for moderately to severely active rheumatoid arthritis and who achieve or maintain a positive clinical response as evidenced by disease activity improvement of at least 20% from baseline in tender joint count, swollen joint count, pain, or disability.

B. Moderately to severely active articular juvenile idiopathic arthritis

Authorization of 12 months may be granted for all members (including new members) with documentation of using the requested medication for moderately to severely active articular juvenile idiopathic arthritis and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:

1. Number of joints with active arthritis (e.g., swelling, pain, limitation of motion)
2. Number of joints with limitation of movement

Effective date: 7/15/2020
Review date: 5/2020, 9/2020, 12/2020, 5/2021, 6/2022, 12/2022, 8/2023, 2/2024, 1/2025
Scope: Medicaid

3. Functional ability

C. Active psoriatic arthritis

Authorization of 12 months may be granted for all members (including new members) with documentation of using the requested medication for active psoriatic arthritis and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:

1. Number of swollen joints
2. Number of tender joints
3. Dactylitis
4. Enthesitis
5. Skin and/or nail involvement

D. Active ankylosing spondylitis (AS) and active axial spondylarthritis

Authorization of 12 months may be granted for all members (including new members) with documentation of using the requested medication for active ankylosing spondylitis or active axial spondylarthritis and who achieve or maintain a positive clinical response with the requested medication as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:

1. Functional status
2. Total spinal pain
3. Inflammation (e.g. morning stiffness)

E. Moderate to severe plaque psoriasis

Authorization of 12 months may be granted for all members (including new members) with documentation of using the requested medication for moderate to severe plaque psoriasis and who achieve or maintain positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when any of the following is met:

1. Reduction in body surface area (BSA) affected from baseline
2. Improvement in signs and symptoms from baseline (e.g., itching, redness, flaking, scaling, burning, cracking, pain)

F. Reactive arthritis

Authorization of 12 months may be granted for all members (including new members) with documentation of using the requested medication for reactive arthritis and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition (e.g., tender joint count, swollen joint count, or pain).

G. Hidradenitis suppurativa

Authorization of 12 months may be granted for all members (including new members) with documentation of using the requested medication for severe, refractory hidradenitis suppurativa and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when any of the following is met:

1. Reduction in abscess and inflammatory nodule count from baseline
2. Reduced formation of new sinus tracts and scarring
3. Decrease in frequency of inflammatory lesions from baseline

Effective date: 7/15/2020
Review date: 5/2020, 9/2020, 12/2020, 5/2021, 6/2022, 12/2022, 8/2023, 2/2024, 1/2025
Scope: Medicaid

4. Reduction in pain from baseline
5. Reduction in suppuration from baseline
6. Improvement in frequency of relapses from baseline
7. Improvement in quality of life from baseline

H. Graft versus host disease

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

I. All other diagnoses

Authorization of 12 months may be granted for all members (including new members) with documentation who are using the requested medication for an indication outlined in Section III and who achieve or maintain positive clinical response with the requested medication as evidenced by low disease activity or improvement in signs and symptoms of the condition.

V. QUANTITY LIMIT

Medication	Standard Limit	FDA-recommended dosing
Enbrel (etanercept) 25 mg per 0.5 mL prefilled syringe	8 syringes per 28 days	RA/PsA/AS <ul style="list-style-type: none"> 50 mg every week PsO <ul style="list-style-type: none"> Loading dose: 50 mg twice a week for 3 months Maintenance dose: 50 mg every week Pediatric PsO/PJIA/JPsA <ul style="list-style-type: none"> Weight < 63 kg: 0.8 mg per kg every week Weight ≥ 63 kg: 50 mg every week
Enbrel 25 mg vial	8 vials per 28 days	
Enbrel (etanercept) 50 mg per 1 mL prefilled syringe/cartridge	8 syringes per 28 days	
Enbrel 50 mg SureClick Autoinjector	8 cartridges per 28 days	

Abbreviations: RA = rheumatoid arthritis; PsA = psoriatic arthritis; AS = ankylosing spondylitis; PsO = plaque psoriasis; PJIA = polyarticular juvenile idiopathic arthritis

VI. APPENDICES

Appendix A: Examples of Contraindications to Methotrexate

1. Alcoholism, alcoholic liver disease or other chronic liver disease
2. Breastfeeding
3. Blood dyscrasias (e.g., thrombocytopenia, leukopenia, significant anemia)
4. Elevated liver transaminases

Effective date: 7/15/2020
Review date: 5/2020, 9/2020, 12/2020, 5/2021, 6/2022, 12/2022, 8/2023, 2/2024, 1/2025
Scope: Medicaid

5. History of intolerance or adverse event
6. Hypersensitivity
7. Interstitial pneumonitis or clinically significant pulmonary fibrosis
8. Myelodysplasia
9. Pregnancy or planning pregnancy
10. Renal impairment
11. Significant drug interaction

Appendix B: Examples of Clinical Reasons to Avoid Pharmacologic Treatment with Methotrexate, Cyclosporine or Acitretin.

1. Alcoholism, alcoholic liver disease, or other chronic liver disease
2. Breastfeeding
3. Drug interaction
4. Cannot be used due to risk of treatment-related toxicity
5. Pregnancy or planning pregnancy
6. Significant comorbidity prohibits use of systemic agents (examples include liver or kidney disease, blood dyscrasias, uncontrolled hypertension)

APPENDIX C: Risk factors for articular juvenile idiopathic arthritis

1. Positive rheumatoid factor
2. Positive anti-cyclic citrullinated peptide antibodies
3. Pre-existing joint damage

VII. REFERENCES

1. Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation; December 2023.
2. van der Heijde D, Ramiro S, Landewe R, et al. 2016 Update of the international ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis.* 2017;0:1-14.
3. Flagg SD, Meador R, Hsia E, et al. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. *Arthritis Rheum.* 2005;53(4):613-617.
4. DRUGDEX® System [Internet database]. Ann Arbor, MI: Truven Health Analytics. Updated periodically. Accessed August 17, 2019.
5. Smolen JS, Landewé R, Billsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis.* 2017;0:1-18.
6. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol.* 2016;68(1):1-26.
7. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum.* 2008;59(6):762-784.
8. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care Res.* 2011;63(4):465-482.

Effective date: 7/15/2020
Review date: 5/2020, 9/2020, 12/2020, 5/2021, 6/2022, 12/2022, 8/2023, 2/2024, 1/2025
Scope: Medicaid

9. Menter A, Gottlieb A, Feldman SR, et al. Guidelines for the management of psoriasis and psoriatic arthritis. Section 1: Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2008;58(5):826-850.
10. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. *J Am Acad Dermatol*. 2011;65(1):137-174.
11. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies; 2015 update. *Ann Rheum Dis*. 2016;75(3):499-510.
12. Gladman DD, Antoni C, P Mease, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. *Ann Rheum Dis*. 2005;64(Suppl II):ii14–ii17.
13. Peluso R, Lervolino S, Vitiello M, et al. Extra-articular manifestations in psoriatic arthritis patients. [Published online ahead of print May 8, 2014]. *Clin Rheumatol*. 2014. Accessed August 22, 2014.
14. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis* 2011;70:896–904.
15. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheumatol*. 2015: 10.1002/art.39298. [Epub ahead of print].
16. Martin PJ, Rizzo JD, Wingard JR, et al. First and second line systemic treatment of acute graft versus host disease: Recommendations of the American Society of Blood and Marrow Transplantation. *Biol Blood Marrow Transplant* 18:1150-1163, 2012.
17. Hatemi G, Christensen R, Bodaghi, et al. 2018 update of the EULAR recommendations for the management of Behcet's syndrome. *Ann Rheum Dis*. 2018.; 77: 808-818.
18. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80(4):1029-1072.
19. Tuberculosis (TB). TB risk factors. Centers for Disease Control and Prevention. Retrieved on 21 June 2019 from: <https://www.cdc.gov/tb/topic/basics/risk.htm>.